Order online now!

www.rockland.com
tech@rockland.com
+1 484.791.3823

Datasheet for 200-302-W57

LAR/PTPRF Antibody Fluorescein

Overview

Description:	Anti-LAR/PTPRF (MOUSE) Monoclonal Antibody Fluorescein Conjugated - 200-302-W57
Item No.:	200-302-W57
Size:	100 µg
Applications:	IHC, WB
Reactivity:	Human, Mouse, Rat
Host Species:	Mouse

Product Details

Background:	PTPRF or leukocyte common antigen-related protein (LAR) is a widely expressed protein tyrosine phosphatase with an extracellular receptor region that resembles a cell adhesion molecule. PTPRF removes phosphate group from β-catenin, an event that may subsequently facilitate cell-cell adhesion and ensure the stability of the cadherin complex. This phosphatase has also been implicated in various cellular processes such as neurite growth, nerve regeneration, actin remodeling and regulation of insulin function (1,2,3,4). Anti-PTPRF (C-terminal) antibody is specific for the extracellular and cytoplasmic subunits of human PTPRF (approx. 210, 150 and 85 kDa). Detection of the PTPRF bands by immunoblotting is specifically inhibited by the immunizing peptide. Anti-PTPRF is ideal for researchers interested in Cell adhesion Cadherin-mediated cell adhesion pathways, PAK pathways, insulin resistance and ureterocele.
Synonyms:	Receptor-type tyrosine-protein phosphatase F, Leukocyte antigen related (LAR), FLJ43335, FLJ45062, FLJ45567, LAR, LAR protein, LARFN5C, LARS, LCA homolog, Leukocyte antigen related (LAR) PTP receptor, Leukocyte antigen related tyrosine phosphatase, Leukocyte common antigen related
Host Species:	Mouse
Conjugate:	Fluorescein (FITC)
Clonality:	Monoclonal
Clone ID:	S165-38
Format:	IgG2a

Target Details

Gene Name:	LAR/PTPRF
Reactivity:	Human, Mouse, Rat
Immunogen Type:	Conjugated Peptide
Immunogen:	Anti-LAR/PTPRF Antibody was produced in mice by repeated immunizations of a fusion peptide consisting of amino acids 1315-1607 of human LAR.
Purity/Specificity:	Anti-LAR/PTPRF Antibody was purified from concentrated tissue culture supernate by Protein G chromatography. BLAST analysis suggests similarity with rat and mouse based on 97% homology with the immunizing sequence. In addition, the sequence was >80% identical to PTPRD and PTPRS, as well as >50% identical to PTPRM and PTPRK.
Relevant Links:	• UniProtKB - P10586 • GeneID - 5792

Application Details

Tested Applications:	IHC, WB
Application Note:	Anti-LAR/PTPRF FITC Conjugated Antibody is tested for use in Western blots and Immunocytochemistry. Expect a band approximately ~85 kDa on specific lysates or tissues. Full protein is 210 kDa; degrades due to proteolysis into p-subunit containing transmembrane and intracellular domains. Specific conditions for reactivity should be optimized by the end user.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:10,000
WB:	1:1000

Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	1mg/mL by UV absorbance at 280 nm

Shipping & Handling

Shipping Condition:	Wet Ice
Storage Condition:	Conjugated antibodies should be stored according to the product label. Product stored in 640.91mM DMSO, 136.36mM Ethanolamine, 9.09mM Sodium Bicarbonate in 90.9% PBS.
Expiration:	Expiration date is one (1) year from date of receipt.

www.rockland.com
tech@rockland.com
+1 484.791.3823

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.